24 Sep 2019 --- The European Commission (EC) has granted UK-based GW Pharmaceuticals (GW) marketing authorization for its cannabidiol (CBD) oral solution for patients with severe forms of epilepsy. Epidyolex is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA). CBD is currently considered an unauthorized novel food in the EU. But this news has been positively received as it may potentially pave the way for further regulatory clarity relating the use of CBD across pharmaceuticals and eventually, supplements and food and beverage.
